Introduction: Obesity, smoking, and alcohol consumption are prevalent in psoriasis patients and have been associated with increased disease severity and reduced treatment adherence and response. This post hoc analysis of pooled data from the phase 3 AMAGINE-2 and -3 trials compared the efficacy of brodalumab versus ustekinumab in psoriasis patients with aggravating and potentially treatment-confounding lifestyle risk factors.

Methods: This post hoc analysis evaluated complete skin clearance, as measured by a 100% reduction of Psoriasis Area and Severity Index (PASI100) and quality of life (QoL), as measured by a Dermatology Life Quality Index (DLQI) score of 0/1, by the presence of risk factors (obesity, tobacco or alcohol use). A competing risk model assessed cumulative incidence over 52 weeks with outcomes of PASI100 or inadequate response.

Results: This analysis included 929 patients (brodalumab 210 mg, n = 339; ustekinumab, n = 590) with moderate-to-severe psoriasis. At week 52, odds ratios (95% confidence intervals [CIs]) for complete clearance with brodalumab versus ustekinumab were 2.50 (1.14–5.46, \( P = 0.0186 \)), 4.64 (2.80–7.69, \( P < 0.0001 \)), 2.06 (1.25–3.40, \( P = 0.0045 \)), and 2.55 (0.55–11.91, \( P = 0.2117 \)) in patients with no, one, two, or three risk factors, respectively. Corresponding odds ratios (ORs) (95% CIs) for DLQI 0/1 with brodalumab versus ustekinumab were 1.72 (0.78–3.79, \( P = 0.1883 \)), 2.49 (1.54–4.02, \( P < 0.0001 \)), 1.57 (0.97–2.54, \( P = 0.0666 \)), and 2.07 (0.45–9.57, \( P = 0.3438 \)). The 52-week cumulative incidence of patients achieving PASI100 was consistently higher for brodalumab versus ustekinumab, regardless of number of risk factors (\( P < 0.0001 \) for one or two risk factors and \( P = 0.0029 \) for three risk factors).

Conclusions: Higher levels of complete skin clearance and QoL were achieved and maintained with brodalumab versus ustekinumab in patients with moderate-to-severe psoriasis, regardless of the presence of lifestyle risk factors.
**Clinical Trial Registration:** AMAGINE-2 (NCT01708603); AMAGINE-3 (NCT01708629).

**Keywords:** Alcohol consumption; Brodalumab; Obesity; Psoriasis; QoL; Skin clearance; Smoking; Ustekinumab

### Key Summary Points

| Why carry out this study? |
|---------------------------|
| Obesity, smoking, and alcohol consumption are prevalent in patients with psoriasis. |
| These lifestyle risk factors have been associated with increased psoriasis severity, limited systemic treatment options, and reduced treatment response. |
| This analysis compared the efficacy of brodalumab versus ustekinumab in patients with moderate-to-severe psoriasis with or without the presence of at least one of these three aggravating lifestyle risk factors at baseline. |

| What was learned from the study? |
|----------------------------------|
| This post hoc analysis of pooled data from the phase 3 AMAGINE-2 and -3 trials found higher levels of complete skin clearance and quality of life were achieved and maintained with brodalumab versus ustekinumab in patients with moderate-to-severe psoriasis, regardless of the presence of lifestyle risk factors. |
| Brodalumab may offer a good treatment option for psoriasis patients who have a history of aggravating lifestyle risk factors. |

### INTRODUCTION

Psoriasis is a chronic inflammatory skin disease with systemic manifestations that has a substantial impact on quality of life (QoL) [1, 2]. While the influence of genetics in psoriasis is well established [3], the extent to which exogenous lifestyle factors such as smoking, alcohol intake, and body mass index (BMI) influence psoriasis pathogenesis is less clear [4].

Alcohol misuse is common in patients with moderate-to-severe psoriasis [approximately > 10% body surface area (BSA) involvement] [5, 6]. Some patients may use alcohol to manage their psychological distress [5], and a correlation between increased alcohol intake and extent of BSA involvement by psoriasis has been shown [5, 6]. Alcohol use has also been linked to the triggering/worsening of psoriasis and poor response to treatment [7].

Evidence suggests that smoking affects the onset of psoriasis [8, 9]. Nicotine also stimulates innate immune cells, including dendritic cells, macrophages, and keratinocytes, which play key roles in the pathogenesis of psoriasis [8]. Random-effects meta-analysis of 25 prevalence studies identified associations between psoriasis and current smoking, and between psoriasis and former smoking [9]. Three incidence studies showed an association between smoking and the incidence of psoriasis, with a possible dose–effect of smoking intensity and duration on psoriasis incidence [9]. Furthermore, smoking has been linked to the clinical severity of psoriasis and response to treatment [10, 11]. Importantly, there is evidence to suggest that smoking may also negatively impact treatment adherence [12, 13]. A systematic review of treatment adherence in patients with psoriasis assessed the role of smoking and identified two studies that reported greater adherence among non-smokers compared with smokers, while a third study reported no association [12]. More recently, registry data have shown being a current smoker to be a predictor of biologic discontinuation [13].

Meta-analyses have shown that higher BMI and obesity are risk factors for psoriasis [14]. In addition, obesity, defined by the World Health Organization as a BMI of 30 kg/m² or above [15], is associated with more severe psoriasis [14].

Moderate-to-severe psoriasis is increasingly treated with biologics that target various cytokines responsible for psoriasis evolution, including interleukin (IL)-17, IL-23, and tumor
necrosis factor (TNF)-\(\alpha\) [16, 17]. While biologics are effective for many patients in the short term [18], some patients fail to respond and 13% of patients discontinue treatment within the first year because of ineffectiveness [13]. Furthermore, as the efficacy of these agents may be negatively impacted by lifestyle factors [17], it is important that lifestyle risk factors are screened for and considered when selecting psoriasis medication [19].

Brodalumab is a fully human monoclonal antibody that binds with high affinity to the IL-17 receptor subunit A (IL-17RA) [20]. By binding to IL-17RA, brodalumab inhibits downstream signaling of multiple IL-17 family cytokines involved in the pathogenesis of psoriasis [20], in contrast to biologics such as secukinumab and ixekizumab, which specifically target IL-17A [21, 22]. In phase 3 trials in patients with moderate-to-severe psoriasis, brodalumab provided high levels of skin clearance for up to 52 weeks [23, 24].

In this post hoc analysis, we evaluated skin clearance and impact on patient QoL over 52 weeks in the phase 3 AMAGINE-2 and -3 studies according to the presence of obesity, tobacco use, and alcohol use. The aims were to compare the efficacy of brodalumab versus ustekinumab in patients with psoriasis with aggravating lifestyle risk factors and to identify lifestyle risk factors that could affect response to therapy.

METHODS

Study Design and Patients

Data were pooled from two phase 3, randomized, double-blind, placebo- and ustekinumab-controlled, 52-week studies of brodalumab (AMAGINE-2 [NCT01708603] and AMAGINE-3 [NCT01708629]). The AMAGINE-2 and -3 study designs have previously been described [24] and are provided in Supplementary Fig. 1. In brief, patients aged \(\geq\) 18 years with moderate-to-severe plaque psoriasis (defined as a Psoriasis Area and Severity Index [PASI] score of \(\geq\) 12, static Physician’s Global Assessment [sPGA] score of \(\geq\) 3 and \(\geq\) 10% BSA involvement of \(\geq\) 6 months duration) were enrolled in the trials. Patients were randomized 2:2:1:1 to receive brodalumab 210 mg, brodalumab 140 mg, or placebo on day 1 and weeks 1, 2, 4, 6, 8 and 10; or ustekinumab (45 mg for patients \(\leq\) 100 kg and 90 mg for patients > 100 kg) on day 1, week 4 and every 12 weeks (Q12W) thereafter. At week 12, brodalumab patients were re-randomized 2:2:2:1 to receive a brodalumab maintenance dose of 210 mg every 2 weeks (Q2W) or 140 mg Q2W every 4 weeks (Q4W) or every 8 weeks (Q8W). Ustekinumab patients continued to receive ustekinumab Q12W, and placebo patients received 210 mg of brodalumab Q2W.

Patients were eligible for rescue treatment with brodalumab 210 mg Q2W if they had an inadequate response (defined as sPGA \(\geq\) 3 or persistent values of 2 over a \(\geq\) 4-week period at, or after, week 16). Rescue treatment was blinded. At week 16, all patients with an inadequate response received rescue treatment with brodalumab 210 mg. After week 16 and through week 52, brodalumab patients were rescued with brodalumab 210 mg Q2W while ustekinumab patients continued to receive ustekinumab. After receiving rescue treatment for \(\geq\) 12 weeks, patients were assessed and discontinued if they were non-responders.

The study protocols were approved by the institutional review boards at each participating center, and the studies were conducted in accordance with the International Conference on Harmonization guideline for Good Clinical Practice, the Declaration of Helsinki, and the Health Insurance Portability and Accountability Act of 1996 or relevant regional regulations. All subjects provided informed consent to participate in the study.

Assessments

Lifestyle Risk Factors

Tobacco and alcohol use were self reported. Patients were categorized as “yes” (current user or stopped within the last year) or “no” (former user/no use). Patients were categorized as obese if they had a BMI of \(\geq 30 \text{ kg/m}^2\).
Table 1 Demographic and baseline characteristics

| Characteristic          | No risk factors | One risk factor | Two risk factors | Three risk factors |
|-------------------------|-----------------|-----------------|------------------|-------------------|
|                         | Brodalumab (n = 51) | Ustekinumab (n = 76) | Brodalumab (n = 140) | Ustekinumab (n = 221) | Brodalumab (n = 122) | Ustekinumab (n = 236) | Brodalumab (n = 26) | Ustekinumab (n = 57) |
| Male, n (%)             | 34 (66.7)       | 48 (63.2)       | 93 (66.4)        | 144 (65.2)        | 82 (67.2)       | 170 (72.0)        | 21 (80.8)       | 42 (73.7)       |
| Age, years              | 47.2 (14.7)     | 40.8 (13.9)     | 44.7 (13.4)      | 45.9 (12.9)       | 43.3 (13.2)     | 46.4 (12.7)       | 44.3 (11.9)     | 42.6 (12.6)     |
| Weight, kg              | 75.5 (10.8)     | 75.8 (12.0)     | 88.0 (23.9)      | 85.7 (19.8)       | 96.7 (26.9)     | 96.9 (23.8)       | 102.5 (12.3)    | 107.5 (23.3)    |
| BMI, kg/m²              | 25.7 (2.8)      | 25.6 (2.7)      | 29.6 (7.7)       | 29.3 (6.4)        | 32.0 (8.2)      | 32.2 (7.6)        | 34.0 (3.1)      | 35.3 (5.4)      |
| White, n (%)            | 48 (94.1)       | 64 (84.2)       | 127 (90.7)       | 200 (90.5)        | 110 (90.2)      | 216 (91.5)        | 23 (88.5)       | 52 (91.2)       |
| Duration of disease, years | 17.4 (10.6) | 18.7 (13.2) | 18.0 (12.0) | 18.5 (11.8) | 16.9 (12.0) | 19.0 (12.6) | 15.2 (11.7) | 17.6 (11.1) |
| BSA, %                  | 26.5 (14.2)     | 29.8 (18.9)     | 27.6 (16.0)      | 27.1 (18.6)       | 27.3 (17.4)     | 27.7 (18.8)       | 23.6 (15.6)     | 25.9 (17.7)     |
| PASI score              | 20.7 (8.4)      | 20.2 (8.3)      | 20.2 (7.2)       | 20.0 (8.3)        | 20.8 (8.5)      | 20.0 (8.5)        | 19.2 (7.3)      | 20.1 (8.2)      |
| DLQI score              | 16.2 (6.5)      | 15.8 (7.1)      | 14.4 (7.3)       | 14.6 (7.5)        | 14.9 (7.7)      | 14.7 (7.1)        | 13.8 (6.4)      | 15.6 (7.4)      |
| NAPSI score             | 8.4 (3.3)       | 7.9 (3.3)       | 9.4 (3.2)        | 9.9 (3.4)         | 9.5 (4.3)       | 9.9 (3.6)         | 9.7 (2.9)       | 11.4 (3.8)      |
| sPGA score              | 3.4 (0.6)       | 3.5 (0.6)       | 3.4 (0.6)        | 3.5 (0.6)         | 3.6 (0.6)       | 3.5 (0.6)         | 3.6 (0.6)       | 3.6 (0.6)       |
| PSI score               | 19.6 (7.2)      | 18.6 (7.1)      | 18.4 (6.9)       | 18.4 (7.1)        | 19.6 (7.4)      | 18.5 (6.7)        | 18.8 (5.6)      | 20.5 (6.3)      |

Data are mean (SD) unless otherwise stated

BMI body mass index, BSA body surface area, DLQI Dermatology Life Quality Index, n number of patients, NAPSI Nail Psoriasis Severity Index, PASI Psoriasis Area and Severity Index, PSI Psoriasis Symptom Inventory, SD standard deviation, sPGA static Physician’s Global Assessment
Disease severity was evaluated using three instruments: the PASI, the Psoriasis Symptom Inventory (PSI), and the sPGA. The PASI is the most commonly used tool for measuring disease activity and treatment effect in clinical trials of biologics to treat psoriasis. While PASI75 (a 75% reduction in the PASI score with respect to baseline) has historically been considered the treatment goal for moderate-to-severe psoriasis [25], studies of newer biologics have included PASI90 and PASI100 as endpoints [23, 24, 26–30]. Patients who achieve PASI100 are more likely to have improved QoL scores and a reduction in the signs and symptoms of psoriasis [24, 31].

The PSI is a patient-reported outcome instrument (developed by Amgen) that measures the severity of psoriasis signs and symptoms. The eight-point questionnaire assesses signs and symptoms of itch, redness, scaling, burning, stinging, cracking, flaking, and pain. Each item is scored on a scale of 0 (not at all severe) to 4 (very severe), giving a total score ranging from 0 (best) to 32 (worst). Response on the PSI is defined as attaining a total score of ≤8, with each symptom rated as either 0 (not at all severe) or 1 (mild) [32]. The sPGA, which assesses erythema, induration, and scaling on a scale from 0 to 5, where 0 indicates clear and 5 indicates severe disease [33], was also used to measure response to treatment. QoL was assessed using the Dermatology Life Quality Index (DLQI). A DLQI score of 0 or 1 indicates no effect at all on patient’s life [34]. PASI, PSI, and DLQI scores were measured at least once every 2–4 weeks throughout the trials.

**Responder Analyses for Clearance (PASI100), DLQI 0/1, and PSI ≤ 8 at a Given Time Point by Risk Factor History**

This analysis included data from patients randomized to receive constant dosing of either the approved dose of brodalumab (210 mg Q2W) or ustekinumab for the entire 52-week treatment period, subdivided according to risk factor history (none, one risk factor, two risk factors, or three risk factors).

Proportions of patients achieving PASI100, PSI ≤ 8 responder status, and DLQI 0/1 are presented according to risk factor history and visit (weeks 0–52 for PASI100 and DLQI 0/1; weeks 0–24 and 48–52 for PSI ≤ 8 responder),

**Table 2 Distribution of lifestyle factors at baseline, by treatment**

| Lifestyle risk factor, n (%) | Brodalumab (n = 339) | Ustekinumab (n = 590) |
|----------------------------|----------------------|-----------------------|
| None                      | 51 (15.0)            | 76 (12.9)             |
| 1                         | 140 (41.3)           | 221 (37.5)            |
| 2                         | 122 (36.0)           | 236 (40.0)            |
| 3                         | 26 (7.7)             | 57 (9.7)              |

| Lifestyle risk factor | Brodalumab (n = 339) | Ustekinumab (n = 590) |
|-----------------------|----------------------|-----------------------|
| Alcohol               | 201 (59.3)           | 383 (64.9)            |
| Smoking               | 111 (32.7)           | 209 (35.4)            |
| Obesity (BMI ≥ 30 kg/m²) | 147 (43.4)     | 271 (45.9)            |
| Weight > 100 kg       | 93 (27.4)            | 166 (28.1)            |

BMI body mass index, n number of patients
with comparisons between treatment groups reported as odds ratios (ORs) and 95% confidence intervals (95% CIs) calculated using the Cochran–Mantel–Haenszel method and adjusted for study, baseline total body weight group (≤ 100 or > 100 kg), geographic region, and within-study and subgroup baseline score (≤ or > median). Non-responder imputation was used to handle missing data.

**Competing Risk Model by Risk Factor History**

The cumulative incidence of complete clearance over 52 weeks was analyzed by risk factor history using a competing risk model [35] with the outcomes of:

(a) Achieving PASI100, or
(b) Inadequate response (defined as sPGA ≥ 3, or sPGA ≥ 2 for > 4 weeks at or after week 16)

Comparisons between treatment arms were performed using subdistribution hazard ratios and associated chi-squared tests [36, 37] and adjusted for baseline characteristics, as detailed for the responder analyses.

**RESULTS**

**Patients**

A total of 929 patients (brodalumab 210 mg, \(n = 339\); ustekinumab, \(n = 590\)) were included in this analysis. Baseline characteristics were generally balanced across treatment and risk groups (Table 1). Baseline PASI, PSI, and DLQI scores were similar across the subgroups.

**Lifestyle Risk Factors**

At baseline, approximately 85% of patients had a history of one or more lifestyle risk factors. In the brodalumab and ustekinumab groups, respectively, 41.3% and 37.5% had a history of one risk factor, 36.0% and 40.0% had a history of two risk factors, and 7.7% and 9.7% had a history of three risk factors (Table 2).

Alcohol use was the most common risk factor: 59.3% and 64.9% of patients in the brodalumab and ustekinumab groups, respectively, had a history of alcohol use. Almost half of the patients in both groups were obese (43.4% and 45.9% in the brodalumab and ustekinumab groups, respectively, Table 2). Further details of tobacco and alcohol use (i.e., light, moderate, or heavy use) are provided in Supplementary Table 1.
### Table 3 Overview of patients with PASI100, PSI response, and DLQI 0/1 at weeks 12 and 52, according to lifestyle risk factors and treatment

| Lifestyle Risk Factors | No risk factors | One risk factor | Two risk factors | Three risk factors |
|-----------------------|----------------|----------------|----------------|-------------------|
|                       | Brodalumab ($n=51$) | Ustekinumab ($n=76$) | OR (95% CI) | Brodalumab ($n=140$) | Ustekinumab ($n=221$) | OR (95% CI) | Brodalumab ($n=122$) | Ustekinumab ($n=236$) | OR (95% CI) | Brodalumab ($n=26$) | Ustekinumab ($n=57$) | OR (95% CI) |
| PASI100 week 12 | 24 (47.1) | 16 (21.1) | 3.54 (1.41–8.87)** | 51 (36.4) | 44 (19.9) | 2.54 (1.52–4.25)*** | 56 (45.9) | 49 (20.8) | 3.59 (2.09–6.17)*** | 10 (38.5) | 12 (21.1) | 1.53 (0.45–5.22) |
| PASI100 week 52 | 29 (56.9) | 26 (34.2) | 2.50 (1.14–5.46)* | 77 (55.0) | 49 (22.2) | 4.64 (2.80–7.69)*** | 56 (45.9) | 76 (32.2) | 2.06 (1.25–3.40)** | 11 (42.3) | 15 (26.3) | 2.55 (0.55–11.91) |
| PSI response week 12 | 37 (72.5) | 47 (61.8) | 2.11 (0.80–5.53) | 89 (63.6) | 117 (52.9) | 1.57 (0.95–2.60) | 76 (62.3) | 134 (56.8) | 1.11 (0.66–1.88) | 20 (76.9) | 30 (52.6) | 2.37 (0.62–9.03) |
| PSI response week 52 | 23 (45.1) | 36 (47.4) | 1.09 (0.48–2.43) | 70 (50.0) | 69 (31.2) | 2.56 (1.55–4.22)*** | 57 (46.7) | 100 (42.4) | 1.45 (0.86–2.45) | 10 (38.5) | 23 (40.4) | 1.03 (0.28–3.85) |
| DLQI 0/1 week 12 | 30 (58.8) | 36 (47.4) | 1.75 (0.75–4.10) | 84 (60.0) | 89 (40.3) | 2.20 (1.37–3.54)*** | 69 (56.6) | 120 (50.8) | 1.14 (0.71–1.81) | 20 (76.9) | 24 (42.1) | 3.54 (0.84–14.92) |
| DLQI 0/1 week 52 | 32 (62.7) | 36 (47.4) | 1.72 (0.78–3.79) | 76 (54.3) | 73 (33.0) | 2.49 (1.54–4.02)*** | 67 (54.9) | 108 (45.8) | 1.57 (0.97–2.54) | 11 (42.3) | 18 (31.6) | 2.07 (0.45–9.57) |

All data are $n$ (%); ORs are brodalumab versus ustekinumab

CI = confidence interval, DLQI = Dermatology Life Quality Index, $n$ = number of patients, OR = odds ratio, PASI = Psoriasis Area and Severity Index, PSI = Psoriasis Symptom Inventory

* $P < 0.05; ** P < 0.01; *** P < 0.001
Responder Analysis for Complete Clearance (PASI100), PSI ≤ 8, and DLQI 0/1 by Number of Lifestyle Risk Factors
Regardless of the presence of risk factors, brodalumab treatment was associated with earlier achievement of complete clearance and consistently higher proportions of complete clearance versus ustekinumab (Fig. 1); differences between the brodalumab and ustekinumab groups were statistically significant for subgroups with no, one, or two baseline risk factors, but did not reach statistical significance in the subgroup with three risk factors. At week 12, PASI100 was achieved by 47.1% of patients on brodalumab versus 21.1% on ustekinumab with no risk factors (OR 3.54, 95% CI 1.41–8.87, \( P = 0.0073 \)), 36.4% versus 19.9% with one risk factor (OR 2.54, 95% CI 1.52–4.25, \( P = 0.0004 \)), 45.9% versus 20.8% with two risk factors (OR 3.59, 95% CI 2.09–6.17, \( P < 0.0001 \)), and 38.5% versus 21.1% with three risk factors (OR 1.53, 95% CI 0.45–5.22, \( P = 0.5127 \)) (Fig. 1, Table 3). At week 52, the proportions of patients in the brodalumab and ustekinumab groups achieving complete clearance were 56.9% versus 34.2% (OR 2.50, 95% CI 1.14–5.46, \( P = 0.0186 \)), 55.0%
versus 22.2% (OR 4.64, 95% CI 2.80–7.69, \( P < 0.0001 \)), 45.9% versus 32.2% (OR 2.06, 95% CI 1.25–3.40, \( P = 0.0045 \)), and 42.3% versus 26.3% (OR 2.55, 95% CI 0.55–11.91, \( P = 0.2117 \)) in the corresponding risk factor groups, respectively.

More patients achieved a PSI response (total PSI \( \leq 8 \)) with brodalumab treatment versus ustekinumab, regardless of risk factor history, at week 12 (Fig. 2). At week 12, 72.5% of patients on brodalumab versus 61.8% on ustekinumab with no risk factors (OR 2.11, 95% CI 0.80–5.53, \( P = 0.1252 \)), 63.6% versus 52.9% with one risk factor (OR 1.57, 95% CI 0.95–2.60, \( P = 0.0742 \)), 62.3% versus 56.8% with two risk factors (OR 1.11, 95% CI 0.66–1.88, \( P = 0.6979 \)), and 76.9% versus 52.6% with three risk factors (OR 2.37, 95% CI 0.62–9.03, \( P = 0.2091 \)) achieved a PSI response (Table 3).

Higher proportions of patients in the brodalumab group achieved DLQI 0/1 compared with the ustekinumab group, independent of baseline risk factors (Fig. 3). At week 12, 58.8% of patients on brodalumab versus 47.4% on ustekinumab with no risk factors (OR 2.11, 95% CI 0.80–5.53, \( P = 0.1252 \)), 63.6% versus 52.9% with one risk factor (OR 1.57, 95% CI 0.95–2.60, \( P = 0.0742 \)), 62.3% versus 56.8% with two risk factors (OR 1.11, 95% CI 0.66–1.88, \( P = 0.6979 \)), and 76.9% versus 52.6% with three risk factors (OR 2.37, 95% CI 0.62–9.03, \( P = 0.2091 \)) achieved a PSI response (Table 3).

Competing Risk Model by Number of Risk Factors

The 52-week cumulative incidence of patients achieving PASI100 was higher for brodalumab versus ustekinumab regardless of the number of risk factors (\( P < 0.0001 \) for one and two risk factors; \( P = 0.0229 \) for three risk factors; Fig. 4).

The median time to achievement of PASI100 in brodalumab patients was not affected by baseline risk factors (Fig. 4). The median time to achieve complete clearance could not be estimated for ustekinumab patients in the one risk factor subgroup, as fewer than 50% of patients achieved complete clearance by week 52.

Responder Analysis for Complete Clearance and DLQI 0/1 by Visit by Various Lifestyle Risk Factors

A higher proportion of brodalumab-treated patients achieved PASI100 in each subgroup through week 52, independent of risk factor (Fig. 5). The ORs (95% CIs) for complete clearance with brodalumab versus ustekinumab at week 52 were: smoking OR 3.59 (2.47–5.20, \( P < 0.0001 \)), alcohol use OR 2.87 (1.75–4.71, \( P < 0.0001 \)), and obesity OR 3.44 (2.33–5.07, \( P < 0.0001 \)). Similarly, a higher proportion of patients in the brodalumab group achieved DLQI 0/1 (Fig. 5) or a PSI response (data not shown) in each risk factor subgroup through week 52. Figure 6 compares ORs and 95% CIs for achieving complete clearance and DLQI 0/1 at weeks 12 and 52, by lifestyle risk factors.

DISCUSSION

Obesity, smoking, and alcohol use are lifestyle risk factors associated with increased psoriasis severity, limited systemic treatment options, and reduced treatment response [6, 7, 10–12, 15]. Obesity may predict biologic treatment discontinuation and lead to lower efficacy of anti-TNF-\( \alpha \) agents [15, 38]. Smoking and obesity have been associated with non-response to anti-TNF-\( \alpha \) therapies, and in a retrospective study of 110 patients with psoriasis
Fig. 5 Percentage of patients achieving a PASI100 and b DLQI 0/1 at weeks 4, 12, and 52 by history of lifestyle risk factors. Pooled data from the AMAGINE-2 and -3 trials. Shading indicates 95% confidence interval. DLQI Dermatology Life Quality Index, PASI Psoriasis Area and Severity Index, Q2W every 2 weeks.
treated with anti-TNF-α therapies, smoking in combination with high BMI and a high baseline PASI score was a risk factor for lack of response [39]. Thus, there is a need for therapeutic strategies that remain effective in patients with aggravating and potentially treatment-con founding lifestyle factors.

In this analysis, which included 929 patients with moderate-to-severe psoriasis from the AMAGINE-2 and -3 studies, approximately 85% of patients had one or more risk factors (obesity or tobacco or alcohol use) at baseline. We assessed the reduction in disease severity (PASI100 and PSI response) and impact on patient QoL, as estimated by the DLQI 0/1, through 52 weeks by obesity (< 30 versus ≥ 30 kg/m²), and/or tobacco use (yes/no), and/or alcohol use (yes/no) per risk group (no risk factors, one risk factor, two risk factors, or three risk factors). We found that complete clearance (PASI100) was achieved more rapidly in more patients treated with brodalumab versus ustekinumab in the subgroups with no, one, or two baseline risk factors.

More patients achieved PSI response (total PSI ≤ 8) or DLQI 0/1 with brodalumab than with ustekinumab through to week 52, but these differences did not reach statistical significance. Thus, while Q12W administration of ustekinumab may be more convenient for patients, these data suggest a trend towards improvements in the severity of psoriasis signs and symptoms with brodalumab treatment.

Responder analysis for complete clearance or DLQI 0/1 by lifestyle risk factors showed a higher proportion of patients achieving PASI100 and DLQI through week 52 with brodalumab treatment in the alcohol use subgroup only. While a trend was observed in the smoking and obesity subgroups, statistical significance was not reached, most likely due to the smaller number of patients in these subgroups compared with the alcohol use subgroup (alcohol use was by far the most common risk factor at baseline).

These findings are similar to those of a previous analysis of AMAGINE-2 and -3 trials showing that treatment with brodalumab resulted in rapid and higher proportions of...
patients achieving complete skin clearance, rapid improvement in QoL, and a greater cumulative benefit for complete skin clearance versus ustekinumab and across subgroups with a history of alcohol and tobacco use [40]. It is possible that lifestyle factors may negatively impact the efficacy of any therapy for patients with psoriasis. However, they had no impact on the demonstrated benefits of brodalumab over ustekinumab in this analysis.

The body of evidence regarding the effects of lifestyle modifications, including weight-loss and smoking-cessation programs as well as trigger-factor elimination, in the management of psoriasis is limited. However, some studies suggest that lifestyle changes, such as a low-calorie diet, may supplement the pharmacologic treatment of obese psoriasis patients [41, 42]. More recently, a systematic review, which included ten randomized controlled trials with 1163 participants, found that dietary intervention may reduce psoriasis severity in obese patients and improve QoL compared with standard care [43].

There are several limitations to this study. The data analyzed were from a clinical trial population with strict entry criteria and may not be representative of real-world patient populations. Notably, AMAGINE-2 and -3 excluded patients who had prior ustekinumab experience, resulting in a high number of biologic-naive patients, and this may have resulted in better response than would be observed in a real-world population [44]. Analyses were of pooled data from clinical trials that were not designed or statistically powered to assess these specific endpoints. Analyses were also restricted to patients in constant treatment arms, reducing the number of available patients that could be included. Finally, PASI is a subjective measure of disease severity. However, participating sites were encouraged to maintain the same rater for each patient to diminish between-rater bias.

CONCLUSIONS

The results of these analyses suggest that higher proportions of patients achieve complete skin clearance, PSI response, and QoL improvement with brodalumab compared with ustekinumab, regardless of history of risk factors, which are extremely common in real-world practice. Furthermore, these higher proportions of response are sustained over time. Thus, brodalumab may offer a good treatment option for psoriasis patients who have a history of aggravating lifestyle risk factors.

ACKNOWLEDGEMENTS

Funding. The brodalumab clinical study programme was sponsored by Amgen/AstraZeneca; this analysis was performed by LEO Pharma. LEO Pharma funded the journal’s Rapid Service fee.

Authorship. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Author Contributions. All authors contributed to the study concept and design. Jes B Hansen performed data collection and statistical analysis. All authors contributed to drafting and critical revision of the manuscript. All authors reviewed and approved the final version of the manuscript.

Medical Writing and Editorial Assistance. Medical writing and editorial assistance were provided by Susan Dyas, MSc, of Adelphi Communications Limited, Macclesfield, UK, and Grace Jeong, PhD of Alphabet Health, New York, NY, funded by LEO Pharma A/S, in accordance with Good Publication Practice (GPP3) guidelines.

Disclosures. Georgios Kokolakis has received honoraria for participation in advisory boards, in clinical trials and/or as speaker from AbbVie Deutschland GmbH & Co. KG, Abbott GmbH, Actelion Pharmaceuticals Ltd., AMGEN GmbH, Basilea Pharmaceutica Ltd., Bayer AG,
Biogen IDEC GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Bristol-Myers Squibb GmbH & Co. KGaA, Celgene GmbH, Hexal AG, Janssen-Cilag GmbH, LEO Pharma GmbH, Lilly Deutschland GmbH, MSD Sharp & Dohme GmbH, Mylan Germany GmbH, Novartis Pharma GmbH, Parexel International GmbH, Pfizer Deutschland GmbH, and UCB Pharma GmbH. Jes B Hansen was an employee of LEO Pharma, and is now affiliated with Radiometer Medical. Kasper Vadstrup is an employee of LEO Pharma. Jose Manuel Carrascosa has received honoraria for participation in advisory boards, in clinical trials and/or as speaker from AbbVie, AMGEN, Biogen, Celgene, Janssen-Cilag, LEO Pharma, Lilly, Novartis Pharma GmbH, Pfizer, UCB, Sandoz, Mylan and Almirall.

Compliance with Ethics Guidelines. The study protocols for the AMAGINE-2 and AMAGINE-3 trials were approved by the institutional review boards at each participating centre. Both studies were conducted in accordance with the International Conference on Harmonisation guideline for Good Clinical Practice, the Declaration of Helsinki, and the Health Insurance Portability and Accountability Act of 1996 or relevant regional regulations. All subjects provided informed consent to participate in the study.

Data Availability. The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

Prior Presentation. These data were previously presented at the 28th European Academy of Dermatology and Venereology (EADV) Congress, 9–13 October 2019, Madrid, Spain.

Open Access. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES

1. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001;137(3):280–4.

2. Greb JE, Goldminz AM, Elder JT, Lebwohl MG, Gladman DD, Wu JJ, et al. Psoriasis. Nat Rev Dis Primers. 2016;2:16082.

3. Kamiya K, Kishimoto M, Sugai J, Komine M, Ohtsuki M. Risk factors for the development of psoriasis. Int J Mol Sci. 2019;20(18):4347.

4. Capon F (2017) The genetic basis of psoriasis. Int J Mol Sci. 18(12):2526

5. Parisi R, Webb RT, Carr MJ, Moriarty KJ, Kleyn CE, Griffiths CEM, et al. Alcohol-related mortality in patients with psoriasis: a population-based cohort study. JAMA Dermatol. 2017;153(12):1256–62.

6. Svanström C, Lonne-Rahm SB, Nordlind K. Psoriasis and alcohol. Psoriasis (Auckl). 2019;9:75–9.

7. Gupta MA, Schork NJ, Gupta AK, Ellis CN. Alcohol intake and treatment responsiveness of psoriasis: a prospective study. J Am Acad Dermatol. 1993;28(5 Pt 1):730–2.

8. Armstrong AW, Armstrong EJ, Fuller EN, Sockolov ME, Voyles SV. Smoking and pathogenesis of psoriasis: a review of oxidative, inflammatory and genetic mechanisms. Br J Dermatol. 2011;165(6):1162–8.

9. Armstrong AW, Harskamp CT, Dhillon JS, Armstrong EJ. Psoriasis and smoking: a systematic review and meta-analysis. Br J Dermatol. 2014;170(2):304–14.
10. Naldi L. Psoriasis and smoking: links and risks. Psoriasis (Auckl). 2016;6:65–71.

11. Richer V, Roubille C, Fleming P, Starnino T, McCourt C, McFarlane A, et al. Psoriasis and smoking: a systematic literature review and meta-analysis with qualitative analysis of effect of smoking on psoriasis severity. J Cutan Med Surg. 2016;20(3):221–7.

12. Thorneloe RJ, Bundy C, Griffiths CE, Ashcroft DM, Cordingley L. Adherence to medication in patients with psoriasis: a systematic literature review. Br J Dermatol. 2013;168(1):20–31.

13. Warren RB, Smith CH, Yiu ZZN, Ashcroft DM, Barker J, Burden AD, et al. Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol. 2015;135(11):2632–40.

14. Paroutoglou K, Papadavid E, Christodoulatos GS, Dalamaga M. Deciphering the association between psoriasis and obesity: current evidence and treatment considerations. Curr Obes Rep. 2020;9(3):165–78.

15. World Health Organization. Body mass index-BMI. Available from: https://www.euro.who.int/en/health-topics/disease-prevention/nutrition/a-healthy-lifestyle/body-mass-index-bmi. Accessed Aug 2020.

16. Gordon KB, Blauvelt A, Foley P, Song M, Wasfi Y, Randazzo B, et al. Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies. Br J Dermatol. 2018;178(1):132–9.

17. Warren RB, Marsden A, Tomenson B, Mason KJ, Soliman MM, Burden AD, et al. Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. Br J Dermatol. 2019;180(5):1069–76.

18. Jabbar-Lopez ZK, Yiu ZZN, Ward V, Exton LS, Mohd Mustapa MF, Samarasekera E, et al. Quantitative evaluation of biologic therapy options for psoriasis: a systematic review and network meta-analysis. J Invest Dermatol. 2017;137(8):1646–54.

19. Mrowietz U, Steinz K, Gerdes S. Psoriasis: to treat or to manage? Exp Dermatol. 2014;23(10):705–9.

20. Russell CB, Rand H, Bigler J, Kerokf K, Timour M, Bautista E, et al. Gene expression profiles normalized in psoriatic skin by treatment with brodalumab, a human anti-IL-17 receptor monoclonal antibody. J Immunol. 2014;192(8):3828–36.

21. Frieder J, Kivelevitch D, Menter A. Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis. Ther Adv Chronic Dis. 2018;9(1):5–21.

22. Syed YY. Ixekizumab: a review in moderate to severe plaque psoriasis. Am J Clin Dermatol. 2017;18(1):147–58.

23. Papp KA, Reich K, Paul C, Blauvelt A, Baran W, Bolduc C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016;175(2):273–86.

24. Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1318–28.

25. Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CE, Nast A, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303(1):1–10.

26. Papp KA, Leonardi CL, Blauvelt A, Reich K, Korman NJ, Ohtsuki M, et al. Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3). Br J Dermatol. 2018;178(3):674–81.

27. Blauvelt A, Reich K, Tsai TF, Tying S, Vanaclocha F, Kingo K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study. J Am Acad Dermatol. 2017;76(1):60-9.e9.

28. Blauvelt A, Papp KA, Griffiths CE, Randazzo B, Wasfi Y, Shen YK, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405–17.

29. Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650–61.

30. Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, et al. Efficacy and safety of...
guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOY-AGE 2 trial. J Am Acad Dermatol. 2017;76(3): 418–31.

31. Strober B, Papp KA, Lebwohl M, Reich K, Paul C, Blauvelt A, et al. Clinical meaningfulness of complete skin clearance in psoriasis. J Am Acad Dermatol. 2016;75(1):77-82.e7.

32. Viswanathan HN, Mutebi A, Milmont CE, Gordon K, Wilson H, Zhang H, et al. Measurement properties of the psoriasis symptom inventory electronic daily diary in patients with moderate to severe plaque psoriasis. Value Health. 2017;20(8):1174–9.

33. Viswanathan HN, Chau D, Milmont CE, Yang W, Erondu N, Revicki DA, et al. Total skin clearance results in improvements in health-related quality of life and reduced symptom severity among patients with moderate to severe psoriasis. J Dermatolog Treat. 2015;26(3):235–9.

34. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3): 210–6.

35. Aalen OO, Johansen S. An empirical transition matrix for non-homogeneous Markov chains based on censored observations. Scand J Stat. 1978;5(3): 141–50.

36. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496–509.